Semi-synthetic platelet gel and method for the preparation thereof

Abstract

A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.

1 .- 12 . (canceled) 
     
     
         13 . A method for the preparation of a semi-synthetic platelet gel comprising:
 a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation,   b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.   
     
     
         14 . The method according to  claim 13 , wherein said platelet activator is selected from the group comprising pharmaceutically acceptable calcium salts and peptides capable of activating the thrombin receptor. 
     
     
         15 . The method according to  claim 13 , wherein said calcium salts are selected from the group comprising calcium chloride and calcium gluconate. 
     
     
         16 . Method The method according to  claim 13 , wherein said peptides capable of activating the thrombin receptor comprise a peptide sequence of from 6 to 14 amino acids. 
     
     
         17 . The method according to  claim 13 , wherein said peptide capable of activating the thrombin receptor comprises the amino acid sequence Ser-Phe-Leu-Leu-Arg-Asn. 
     
     
         18 . The method according to  claim 13 , wherein said addition of the mixture to the biocompatible polymer is performed within 15 minutes of said treatment with said platelet activator. 
     
     
         19 . The method according to  claim 13 , wherein said biocompatible polymer is selected from the group comprising polyethylene glycols, poloxamers, polyvinyl pyrrolidone, hyaluronic acid, benzyl hyaluronate esters, crosslinked hyaluronic acid, hydroxymethylcellulose, hydroxyethylcellulose and carboxymethylcellulose. 
     
     
         20 . The method according to  claim 13 , wherein said biocompatible polymer is in the form of a solution or dispersion in water. 
     
     
         21 . The method according to  claim 13 , wherein said biocompatible polymer is in the form of a dressing or fibrous matrix. 
     
     
         22 . The method according to  claim 13 , wherein said biocompatible polymer is in the form of gel. 
     
     
         23 . The method according to  claim 13 , wherein said at least one pharmaceutically useful compound is selected from the group comprising healing agents, disinfectants, antibiotics, anti-inflammatory agents, analgesics, local anaesthetics, opioids, and anabolic agents is added to said semi-synthetic platelet gel. 
     
     
         24 . A method for preparing a platelet gel comprising:
 a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation,   b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof;   wherein said platelet gel comprises:   a platelet-rich plasma containing at least 1 million platelets per microliter of plasma, an amount of at least one platelet activator that activates the release of platelet growth factors, but is not capable of forming a clot in less than 15 minutes, and   at least one biocompatible polymer selected from the group consisting of carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, polyethylene glycols, hyaluronic acid, benzyl hyaluronate esters, crosslinked hyaluronic acid, hydroxymethylcellulose, hydroxyethylcellulose carboxymethylcellulose; and derivatives thereof;   wherein the platelets in said platelet-rich plasma have been activated to release platelet growth factors by said activator, and   wherein said biocompatible polymer is mixed with the activated platelets to form said platelet gel before the start of clot formation.   
     
     
         25 . A surgical method or wound healing method comprising:
 administering to a subject in need thereof a platelet gel comprising:   a platelet-rich plasma containing at least 1 million platelets per microliter of plasma, an amount of at least one platelet activator that activates the release of platelet growth factors, but is not capable of forming a clot in less than 15 minutes, and   at least one biocompatible polymer selected from the group consisting of carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, polyethylene glycols, hyaluronic acid, benzyl hyaluronate esters, crosslinked hyaluronic acid, hydroxymethylcellulose, hydroxyethylcellulose carboxymethylcellulose; and derivatives thereof;   wherein the platelets in said platelet-rich plasma have been activated to release platelet growth factors by said activator, and   wherein said biocompatible polymer is mixed with the activated platelets to form said platelet gel before the start of clot formation.   
     
     
         26 . The method of  claim 25 , wherein said subject has a diabetic, vascular or decubitus ulcer. 
     
     
         27 . The method of  claim 25 , wherein said subject is recovering from heart surgery. 
     
     
         28 . The method of  claim 25 , wherein said subject has a fracture or pseudarthrosis. 
     
     
         29 . The method of  claim 25 , wherein said subject is undergoing surgery involving reconstruction of muscle and/or bone. 
     
     
         30 . The method of  claim 25 , wherein said subject is recovering from implantation of a prosthesis.